Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2023 · 10-Q
Revenue$1.10M$1.10M−31.9% vs Q2 2022 Net Income-$593.03K-$593.03KN/M vs Q2 2022 EPS Diluted-$0.35-$0.35N/M vs Q2 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$216,435N/M Margins · derivedGross margin-13.4%+0.9 pt vs Q2 2022
Operating margin-41.6%+6.8 pt vs Q2 2022
Net margin-54.0%+1.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end